159 related articles for article (PubMed ID: 15965925)
21. Suppression of beta-catenin mutation by dietary exposure of auraptene, a citrus antioxidant, in N,N-diethylnitrosamine-induced hepatocellular carcinomas in rats.
Hara A; Sakata K; Yamada Y; Kuno T; Kitaori N; Oyama T; Hirose Y; Murakami A; Tanaka T; Mori H
Oncol Rep; 2005 Aug; 14(2):345-51. PubMed ID: 16012713
[TBL] [Abstract][Full Text] [Related]
22. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.
Zucman-Rossi J; Jeannot E; Nhieu JT; Scoazec JY; Guettier C; Rebouissou S; Bacq Y; Leteurtre E; Paradis V; Michalak S; Wendum D; Chiche L; Fabre M; Mellottee L; Laurent C; Partensky C; Castaing D; Zafrani ES; Laurent-Puig P; Balabaud C; Bioulac-Sage P
Hepatology; 2006 Mar; 43(3):515-24. PubMed ID: 16496320
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
Zucman-Rossi J; Benhamouche S; Godard C; Boyault S; Grimber G; Balabaud C; Cunha AS; Bioulac-Sage P; Perret C
Oncogene; 2007 Feb; 26(5):774-80. PubMed ID: 16964294
[TBL] [Abstract][Full Text] [Related]
24. Genetic alterations of Wnt signaling pathway-associated genes in hepatocellular carcinoma.
Kim YD; Park CH; Kim HS; Choi SK; Rew JS; Kim DY; Koh YS; Jeung KW; Lee KH; Lee JS; Juhng SW; Lee JH
J Gastroenterol Hepatol; 2008 Jan; 23(1):110-8. PubMed ID: 18171349
[TBL] [Abstract][Full Text] [Related]
25. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects.
Buendia MA
Med Pediatr Oncol; 2002 Nov; 39(5):530-5. PubMed ID: 12228912
[TBL] [Abstract][Full Text] [Related]
26. Novel candidate targets of Wnt/beta-catenin signaling in hepatoma cells.
Lee HS; Park MH; Yang SJ; Park KC; Kim NS; Kim YS; Kim DI; Yoo HS; Choi EJ; Yeom YI
Life Sci; 2007 Jan; 80(7):690-8. PubMed ID: 17157329
[TBL] [Abstract][Full Text] [Related]
27. Human p53 knock-in (hupki) mice do not differ in liver tumor response from their counterparts with murine p53.
Jaworski M; Hailfinger S; Buchmann A; Hergenhahn M; Hollstein M; Ittrich C; Schwarz M
Carcinogenesis; 2005 Oct; 26(10):1829-34. PubMed ID: 15917304
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms of liver carcinogenesis in the mdr2-knockout mice.
Katzenellenbogen M; Mizrahi L; Pappo O; Klopstock N; Olam D; Jacob-Hirsch J; Amariglio N; Rechavi G; Domany E; Galun E; Goldenberg D
Mol Cancer Res; 2007 Nov; 5(11):1159-70. PubMed ID: 18025261
[TBL] [Abstract][Full Text] [Related]
29. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.
Tissier F; Cavard C; Groussin L; Perlemoine K; Fumey G; Hagneré AM; René-Corail F; Jullian E; Gicquel C; Bertagna X; Vacher-Lavenu MC; Perret C; Bertherat J
Cancer Res; 2005 Sep; 65(17):7622-7. PubMed ID: 16140927
[TBL] [Abstract][Full Text] [Related]
30. Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis.
Park JY; Park WS; Nam SW; Kim SY; Lee SH; Yoo NJ; Lee JY; Park CK
Liver Int; 2005 Feb; 25(1):70-6. PubMed ID: 15698401
[TBL] [Abstract][Full Text] [Related]
31. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice.
Anna CH; Iida M; Sills RC; Devereux TR
Toxicol Appl Pharmacol; 2003 Jul; 190(2):135-45. PubMed ID: 12878043
[TBL] [Abstract][Full Text] [Related]
32. Proteome analysis of chemically induced mouse liver tumors with different genotype.
Strathmann J; Paal K; Ittrich C; Krause E; Appel KE; Glauert HP; Buchmann A; Schwarz M
Proteomics; 2007 Sep; 7(18):3318-31. PubMed ID: 17722141
[TBL] [Abstract][Full Text] [Related]
33. Comparative transcriptome and proteome analysis of Ha-ras and B-raf mutated mouse liver tumors.
Rignall B; Ittrich C; Krause E; Appel KE; Buchmann A; Schwarz M
J Proteome Res; 2009 Aug; 8(8):3987-94. PubMed ID: 19476384
[TBL] [Abstract][Full Text] [Related]
34. Zonation of heme synthesis enzymes in mouse liver and their regulation by β-catenin and Ha-ras.
Braeuning A; Schwarz M
Biol Chem; 2010 Nov; 391(11):1305-13. PubMed ID: 20707599
[TBL] [Abstract][Full Text] [Related]
35. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
36. Proliferation and migration mediated by Dkk-1/Wnt/beta-catenin cascade in a model of hepatocellular carcinoma cells.
Qin X; Zhang H; Zhou X; Wang C; Zhang H; Zhang X; Ye L
Transl Res; 2007 Nov; 150(5):281-94. PubMed ID: 17964517
[TBL] [Abstract][Full Text] [Related]
37. Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations.
Audard V; Grimber G; Elie C; Radenen B; Audebourg A; Letourneur F; Soubrane O; Vacher-Lavenu MC; Perret C; Cavard C; Terris B
J Pathol; 2007 Jul; 212(3):345-52. PubMed ID: 17487939
[TBL] [Abstract][Full Text] [Related]
38. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.
Cazals-Hatem D; Rebouissou S; Bioulac-Sage P; Bluteau O; Blanché H; Franco D; Monges G; Belghiti J; Sa Cunha A; Laurent-Puig P; Degott C; Zucman-Rossi J
J Hepatol; 2004 Aug; 41(2):292-8. PubMed ID: 15288479
[TBL] [Abstract][Full Text] [Related]
39. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations.
Harada N; Oshima H; Katoh M; Tamai Y; Oshima M; Taketo MM
Cancer Res; 2004 Jan; 64(1):48-54. PubMed ID: 14729607
[TBL] [Abstract][Full Text] [Related]
40. B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Jaworski M; Buchmann A; Bauer P; Riess O; Schwarz M
Oncogene; 2005 Feb; 24(7):1290-5. PubMed ID: 15592514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
